

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**PURCHASE OF SHARES BY CHIA TAI TIANQING**  
**UNDER THE SHARE INCENTIVE SCHEME**

Reference is made to the announcement of Sino Biopharmaceutical Limited (the “**Company**”) dated 7 May 2024 (the “**Announcement**”) in relation to the implementation of the Share Incentive Scheme by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**Chia Tai Tianqing**”), a subsidiary of the Company. Unless the context otherwise requires, the capitalised terms used herein shall have the same meanings as defined in the Announcement.

From 8 October 2024 to 9 October 2024, the Trustee further purchased a total of 21,000,000 shares of the Company on the market in accordance with the terms and conditions of the Share Incentive Scheme for subsequent implementation of share-based incentives for the Selected Participants. Details of the Shares purchased during the above-mentioned period and held on trust by the Trustee are set out below:

Total number of Shares purchased:	21,000,000 shares
Percentage of the Shares purchased to the existing total number of Shares in issue:	Approximately 0.11%
Average consideration per Share:	Approximately HKD3.81
Total consideration for the Shares purchased:	Approximately HKD79,921,000

The board of directors of Chia Tai Tianqing will from time to time review and determine in its absolute discretion the number of Shares to be granted to the Selected Participants and subject to such vesting conditions as it may deem appropriate, and the number of Shares to be further purchased on the market under the Share Incentive Scheme.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 9 October 2024

*As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*